Subscribe
Komsan Loonprom / Shutterstock.com
11 September 2025NewsAmericasMuireann Bolger

Sandoz eyes US biosimilar launch as Regeneron settles

Deal resolves just one case in Regeneron’s roll-call of actions against competitors looking to launch versions of a $6bn-a-year blockbuster eye-disease treatment.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Regeneron hits Amgen over its blockbuster eye disease treatment
19 June 2025   The biotech firm strikes again over Eylea after Amgen launches biosimilar | Regeneron claims Amgen infringed agreed ‘patent dance’ | Follows other lawsuits aimed at protecting Eylea.
Americas
Regeneron edges closer to Eylea market exclusivity amid biosimilar threats
6 March 2025   New York biotech scores win as Fed Circ upholds preliminary injunction against Celltrion's biosimilar launch | Ruling follows intense scrutiny during Federal Circuit oral arguments | Decision follows similar rulings against Samsung Bioepis and Formycon.
Americas
Courtroom report: Regeneron’s $6bn biosimilar battle against Mylan
13 February 2025   The company’s Eylea treatment patent faced intense scrutiny as the US Federal Circuit heard Williams & Connolly, RMMS Legal, and McGuireWoods argue over criticality, stability, and validity.


Editor's picks

Data and delivery: Inside AI's inventorship dilemma
Americas
Data and delivery: Inside AI's inventorship dilemma
21 October 2025

Editor's picks

Americas
Data and delivery: Inside AI's inventorship dilemma
21 October 2025
Big Pharma
Moderna TM counsel: Commoditising work using AI is a ‘moral obligation’
16 October 2025
Americas
‘Death knell’ for investment: Universities warn against Lutnick’s royalty sharing proposal
13 October 2025
Americas
IP agencies vital to pharma and biotech grind to a halt
2 October 2025
Americas
Global vaccine patents rise, as data reveals shift in Big Pharma strategy
1 October 2025
Americas
Killing the golden goose of US drug innovation (Part II): Drug pricing myths
12 September 2025

More features

Less is more: patent lawyers flip the script after Amgen
‘Doing more with less’: In-house counsel on budgets and strategy
End of the ‘Death Squad’? Squires puts PTAB on trial
Data and delivery: Inside AI's inventorship dilemma
Weil continues expansion with top trade secrets litigator
Top pharma, biotech, and medtech experts gather at LSPN Fall
Mitsubishi Tanabe doubles down on Radicava protection
‘All it takes is a post on Truth Social’: Is this patent reform's moment?